Full-Time

Director – Corporate Income Tax Compliance

Posted on 4/7/2025

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior, Expert

London, UK + 2 more

More locations: Cambridge, UK | Welwyn Garden City, UK

Employees are expected to work in the office a minimum of three days per week, indicating a hybrid work model.

Category
Tax Accounting
Accounting
Requirements
  • Qualified, experienced tax professional with a strong understanding of the international tax landscape, knowledge of both UK and US tax helpful
  • Leadership and development of a global specialist team
  • Excellent communication and interpersonal skills, with the ability to influence cross-functional teams and senior management.
Responsibilities
  • Define corporate income tax strategy - Develop and implement global tax strategies to ensure compliance with corporate income tax laws and regulations globally, including key jurisdictions, e.g. UK, US and Sweden, whilst optimising the company’s overall tax burden, including identifying tax incentives and opportunities aligning with business goals.
  • Manage compliance - Oversee the preparation and submission of accurate and timely tax returns and tax disclosures in local GAAP financial statements prepared by our Outsource Provider and supported by our wider finance organisation.
  • Manage corporate income tax risk - Identify, assess, and mitigate tax-related risks. Develop and maintain tax risk management frameworks and policies.
  • Lead and mentor a global team, fostering a culture of excellence and continuous development.
  • Leverage technology and optimise our corporate income tax processes – Embed a culture of continuous process improvement, encourage best practices sharing across regions and ensure that data, systems and processes are appropriate and controlled.
  • Business partner with wider tax team, finance, legal, and business units to ensure corporate income tax considerations are integrated into business decisions.

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatment; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before reaching the market. AstraZeneca distinguishes itself from competitors by investing heavily in scientific research and fostering collaborations through initiatives like their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through strategic partnerships.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery enhances AstraZeneca's R&D efficiency.
  • Real-world evidence streamlines AstraZeneca's drug approval processes.
  • Personalized medicine aligns with AstraZeneca's focus on precision therapies.

What critics are saying

  • Class-action lawsuit over Soliris could lead to financial penalties.
  • AI tool for breast cancer screening may face effectiveness challenges.
  • Foreign investment regulations in France may impact Dunkirk expansion.

What makes AstraZeneca unique

  • AstraZeneca excels in oncology, cardiovascular, and respiratory therapy areas.
  • The A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • Open Innovation program accelerates drug discovery through shared resources.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Cision
Apr 22nd, 2025
Enhertu Combination Improved Pfs In 1L Her2+ Mbc

Enhertu combination improved PFS in 1L HER2+ mBC

Life Sciences IP Review
Apr 17th, 2025
AstraZeneca unit faces class-action suit over alleged Soliris monopoly

AstraZeneca unit faces class-action suit over alleged soliris monopoly.

Our Health Needs
Apr 11th, 2025
Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation

In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

Medical Update Online
Apr 11th, 2025
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025

AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.

Cision
Apr 11th, 2025
Result Of Agm

11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast

INACTIVE